reshapelifesciences.com (HIND) - Market Value to Book Value Ratio
The market capitalization to book value ratio demonstrates the current asset valuation of Vyome Holdings Inc (HIND), where the value 2.11 captures this metric. This trend relies on the brand's authority in developing treatments for resistant skin infections. While management aims to implement innovations in acne treatment, the integration of various divisions and a liquidity shortage create significant operational challenges for the holding company.
Vyome Holdings Inc. (HIND) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization indicators:
- book capitalization data:
- debt obligations and liquidity statistics:
Debt to Equity Vyome Holdings Inc|HIND - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ReShape Lifesciences|HIND - Company Total Debt|Debts to Book Capitalization ReShape Lifesciences|HIND - Company Long-Term Debts|Company Current Liabilities Vyome Holdings|Quick Ratio reshapelifesciences.com
- earnings and valuation multiples indicators:
Basic company analysis:Vyome Holdings Inc - HIND
For a long-term investor, the reliability of Vyome Holdings Inc (HIND) depends on the balance between tangible assets and market expectations. This metric is calculated as the ratio of the total market capitalization to the value of shareholders' equity. An analysis of the premium of the market valuation over the book value demonstrates the extent of the premium paid for future R&D success. In an environment of fierce competition with pharma behemoths, an inflated coefficient signals risks in the event of failed drug trials. The stability of this ratio confirms the resilience of the business.
Competitor analysis
ARGX: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio BNTX|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|nektar.com (NKTR) - Market Cap to Net Assets Ratio|Upstream Bio (UPB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|Market Cap to Net Assets Ratio IMNM|Market Capitalization to Book Value Ratio Gossamer Bio Corp.|Market Value to Book Value Ratio KalVista Pharmaceuticals (KALV)|septerna.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PVLA (Pieris Pharmaceuticals, Inc.)|Savara Inc (SVRA) - Market-to-Book Ratio|RIGL: Market Cap to Net Assets Ratio|ANAB: Market Value to Book Value Ratio|ATXS (Astria Therapeutics) - Market Cap to Net Assets Ratio|Market-to-Book Ratio engene.com (ENGN)|Market Value to Book Value Ratio RAPT Therapeutics|Market-to-Book Ratio Aerovate JBIO|Market Value to Book Value Ratio Aclaris (ACRS)|Market Cap to Net Assets Ratio Kyverna Therapeutics, Inc KYTX|Market Capitalization to Book Value Ratio TLSA (Tiziana Life Sciences)|cabalettabio.com (CABA) - Market-to-Book Ratio|VTYX: Market Cap to Net Assets Ratio|Market Value to Book Value THTX (Theratechnologies, Inc.)|AVTX: Market Capitalization to Book Value Ratio|Eledon Pharmaceuticals, Inc - Market Value to Book Value|Market Value to Book Value Ratio Agenus|Market-to-Book Ratio climbbio.com CLYM|Market Value to Book Value Ratio Zura Bio (ZURA)|Market Value to Book Value Ratio ATYR (aTyr Pharma Inc)|Market Capitalization to Book Value Ratio ADAG (Adagene Inc.)|IMA: Capitalization to Book Value Ratio|Shattuck Therapeutics - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Equillium, Inc. EQ|connectbiopharm.com (CNTB) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio IMUX|ATRA (Atara Biotherapeutics, Inc.) - Market Capitalization to Book Value Ratio|IFRX - Market Value to Equity Ratio|Market Value to Book Value Ratio X4 Pharmaceuticals (XFOR)|Market Capitalization to Book Value adicetbio.com|Celularity - Market Cap to Net Assets Ratio|Market Value to Book Value INMB|Barinthus Bio - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Kezar Life Sciences Inc KZR|SAB Biotherapeutics (SABS) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio AKTX|ENLV (Enlivex Therapeutics Ltd) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Q32 Bio Corp (QTTB)|Market Capitalization to Book Value Ratio GOVX|EDSA (Edesa Biotech Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio IBIO (iBio, Inc.)|Market Capitalization to Book Value Carisma Therapeutics Inc (CARM)|XTLB - Market Value to Book Value Ratio|BOLT (Bolt Biotherapeutics) - Capitalization to Book Value Ratio|HCWB: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio APVO|Market Value to Book Value Ratio AIM ImmunoTech Inc.|Aditxt Corp - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio GRI|XRTX (XORTX Therapeutics Inc) - Market Value to Book Value|Market Capitalization to Book Value Ratio REVB (Revelation Bio)|Market Capitalization to Book Value Ratio Indaptus Corp INDP|SCNI - Market Value to Book Value Ratio|Market Value to Book Value CALI (CalciMedica, Inc.)|affimed.com (AFMD) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Allakos|HOOK (HOOKIPA Pharma, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio IGM Bio|Market Cap to Net Assets Ratio ITOS (iTeos Therapeutics)|OCEA (oceanbiomedical.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio TCBP (TC BioPharm)|Market Capitalization to Book Value Third Harmonic Bio Inc. (THRD)